- Niraparib Maintenance Produces Long-Term Benefit in Advanced Ovarian Cancer, Irrespective of HRD Status.
- Scott R, González-Martín A.
- OncLive. 2022 Oct 12.
- Review. Interview
- Free Full Text
Conference abstract:
530P PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety.
Identifier: NCT02655016: A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy. (ClinicalTrials.gov . Accessed 2022 Oct 12.)
Video: Dr. González-Martín on Updated PFS Data From the PRIMA Trial in Advanced Ovarian Cancer. (OncLive TV)
- A novel germline mutation of TP53 with breast cancer diagnosed as Li-Fraumeni syndrome.
- Kai M, Kubo M, Shikada S, Hayashi S, Morisaki T, Yamada M, Takao Y, Shimazaki A, Harada Y, Kaneshiro K, Mizuuchi Y, Shindo K, Nakamura M.
- Surg Case Rep. 2022 Oct 11;8(1):197. doi: 10.1186/s40792-022-01546-y.
- PMID: 36219266
- PubMed abstract
- Case report
- Free Full Text